Daiichi Sankyo names Hiroyuki Okuzawa as CEO
Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.
Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative Director, President and CEO.
Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three of the largest licensing deals in history along with the approvals of ENHERTU and DATROWAY, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC Technology.
Daiichi Sankyo’s five-year business plan (FY2021-2025) is progressing successfully with the rapid and global expansion of its oncology business. In order to ensure the solid achievement of FY2025 goals and to strengthen its management structure, Daiichi Sankyo’s Board of Directors appointed Mr. Okuzawa as the new CEO at the board meeting on January 31, 2025, based on the Nomination Committee’s report.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.